Cyclodextrins in ophthalmic drug delivery

Advanced Drug Delivery Reviews

Volumn 36, Issue 1, 1999, Pages 59-79

  Loftssona, Thorsteinn ^a   Järvinen, Tomi ^b  

^a UNIVERSITY OF ICELAND   (Iceland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Corneal permeability; Eye; Ocular absorption; Ocular irritation; Penetration enhancer; Solubility; Stability; Topical administration; Water soluble polymer

Indexed keywords

DERIVATIVES; DRUG INFUSION; DRUG PRODUCTS; OPHTHALMOLOGY; SOLUBILITY; SOLUTIONS;

CYCLODEXTRINS; OPHTALMIC DRUG DELIVERY;

POLYSACCHARIDES;

ACETAZOLAMIDE; AGENTS ACTING ON THE EYE; ANANDAMIDE; CETIRIZINE; CYCLODEXTRIN DERIVATIVE; CYCLOSPORIN; DEXAMETHASONE; DIPIVEFRINE; EYE DROPS; HYDROCORTISONE; PILOCARPINE; PROSTAGLANDIN DERIVATIVE;

COMPLEX FORMATION; CORNEA; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG SAFETY; DRUG SOLUBILITY; DRUG STABILITY; EYE; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0344286485     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(98)00055-6     Document Type: Review

References (122)

1. I. Loftsson, E. Stefánsson, Effect of cyclodextrins on topical drug delivery to the eye, Drug Devel. Ind. Pharm. 23 (1997) 473-481.
2. R.A. Rajewski, V.J. Stella, Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery, J. Pharm. Sci. 85 (1996) 1142-1168.
3. H. van Dorne, Interaction between cyclodextrins and ophthalmic drugs, Eur. J. Pharm. Biopharm. 39 (1993) 133-139.
4. V.J. Stella, R.A. Rajewski, Cyclodextrins: their future in drug formulation and delivery, Pharm. Res. 14 (1997) 556-567.
5. V.H.L. Lee, J.R. Robinson, Mechanistic and quantitative evaluation of precorneal pilocarpine disposition in albino rabbits, J. Pharm. Sci. 68 (1979) 673-684.
6. V.H.L. Lee, J.R. Robinson, Topical ocular drug delivery: recent developments and future challenges, J. Ocul. Pharmacol. 2 (1986) 67-108.
7. D.M. Maurice, S. Mishima, Ocular pharmacokinetics, in: M.C Sears (Ed.), Handbook of Experimental Pharmacology, vol. 69, Springer-Verlag, Berlin-Heidelberg, 1984, pp. 19-116.
8. T. Järvinen, K. Järvinen, A. Urtti, Ocular absorption following topical delivery, Adv. Drug Del. Rev. 16 (1995) 3-19.
9. A. Urtti, L. Salminen, Minimizing systemic absorption of topically administered ophthalmic drugs, Surv. Ophthalmol. 37 (1993) 435-456.
10. S.S. Chrai, T.F. Patton, A. Mehta, J.R. Robinson, Lacrimal and instilled fluid dynamics in rabbit eye, J. Pharm. Sci. 62 (1973) 1112-1121.
11. T.F. Patton, J.R. Robinson, Influence of topical anesthesia on tear dynamics and ocular drug bioavailability in albino rabbits, J. Pharm. Sci. 64 (1975) 267-271.
12. T.F. Patton, J.R. Robinson, Quantitative precorneal disposition of topically applied pilocarpine nitrate in rabbit eyes, J. Pharm. Sci. 65 (1976) 1295-1301.
13. J.L. Greaves, O. Olejnik, C.G. Wilson, Polymers and the precorneal tear film, S.T.P. Pharm. Sci. 2 (1992) 13-33.
14. I. Zaki, P. Fitzgerald, J.G. Hardy, C.G. Wilson, A comparison of the effect of viscosity on the precomeal residence of solutions in rabbit and man, J. Pharm. Pharmacol. 38 (1986) 463-466.
15. A. Ludwig, M. Van Ooteghem, The evaluation of viscous ophthalmic vehicles by slit lamp fluorophotometry in humans, Int. J. Pharm. 54 (1989) 95-102.
16. A. Ludwig, N. LJnIu, M. Van Ooteghem, Evaluation of viscous ophthalmic vehicles containing carbomer by slit-lamp fluorophotometry in humans, Int. J. Pharm. 61 (1990) 15-25.
17. M.F. Sugrue, The pharmacology of antiglaucoma drugs, Pharm. Ther. 43 (1989) 91-138.
18. M.A. Watsky, M.M. Jablonski, H.F. Edelhauser, Comparison of conjunctival and corneal surface areas in rabbit and human, Curr. Eye Res. 7 (1988) 483-486.
19. I. Ahmed, R.D. Gokhale, MV. Shah, T.F. Patton, Physicochemical determinants of drug diffusion across the conjunctiva, sclera, and cornea, J. Pharm. Sci. 76 (1987) 583-586.
20. W. Wang, H. Sasaki, D.-S. Chien, V.H.L. Lee, Lipophilicity influence on conjunctival drug penetration in the pigmented rabbit: a comparison with corneal penetration, Curr. Eye Res. 10 (1991) 571-579.
21. M.G. Doane, A.D. Jensen, C.H. Dohlman, Penetration routes of topically applied eye medication, Am. J. Ophthalmol. 85 (1978) 383-386.
22. P. Ashton, S.K. Podder, V.H.L. Lee, Formulation influence on conjunctival penetration of four beta-blockers in the pigmented rabbit: a comparison with corneal penetration, Pharm. Res. 8 (1991) 1166-1174.
23. Y. Rojanasakul, L.-Y. Wang, M. Bhat, D.D. Glover, C.J. Malanga, J.K.H. Ma, The transport barrier of epithelia: a comparative study on membrane permeability and charge selectivity in the rabbit, Pharm. Res. 9 (1992) 1029-1034.
24. H.-S. Huang, R.D. Schoenwald, J.L. Lach, Corneal penetration behavior of beta-blocking agents II: assessment of barrier contributions, J. Pharm. Sci. 72 (1983) 1272-1286.
25. S.-C. Chang, Prodrug and Vehicle approaches to Improve the Therapeutic Index of Topically Applied Timolol in the Pigmented Rabbit, School of Pharmacy, University of Southern California, Los Angeles, 1987.
26. R.D. Schoenwald, H.-S. Huang, Corneal penetration behaviour of β-blocking agents. I: physicochemical factors, J. Pharm. Sci. 72 (1983) 1266-1272.
27. R.D. Schoenwald, R. Ward, Relationship between steroid permeability across excited rabbit cornea and octanol-water partition coefficients, J. Pharm. Sci. 67 (1978) 786-788.
28. J.W. Sieg, J.R. Robinson, Vehicle effects on ocular drug bioavailability II: evaluation of pilocarpine, J. Pharm. Sci. 66 (1977) 1222-1228.
29. J. Liaw, J.R. Robinson, The effect of polyethylene glycol molecular weight on corneal transport and the related influence of penetration enhancers, Int. J. Pharm. 88 (1992) 125-140.
30. J. Liaw, Y. Rojanasakul, J.R. Robinson, The effect of drug charge type and charge density on corneal transport, Int. J. Pharm. 88 (1992) 111-124.
31. T.H. Maren, L. Jankowska, Ocular pharmacology of sulfonamides: the cornea as barrier and depot, Curr. Eye Res. 4 (1985) 399-408.
32. W.F. Brechue, T.H. Maren, pH and drug ionization affects ocular pressure lowering of topical carbonic anhydrase inhibitors, Invest. Ophthalmol. Vis. Sci. 34 (1993) 2581-2587.
33. L.G. Carney, R.M. Hill, Human tear buffering capacity, Arch. Ophthalmol. 97 (1979) 951-952.
34. A. Longwell, S. Birss, N. Keller, D. Moore, Effect of topically applied pilocarpineon tear film pH, J. Pharm. Sci. 65 (1976) 1654-1657.
35. I. Ahmed, T. Patton, Effect of pH and buffer on the precorneal disposition and ocular penetration of pilocarpine in rabbits, Int. J. Pharm. 19 (1984) 215-227.
36. H. Benson, P. Alto, Permeability of the cornea to topically applied drugs, Arch. Ophthalmol. 91 (1974) 313-327.
37. T. Irie, K. Uekama, Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation, J. Pharm. Sci. 86 (1997) 147-162.
38. T.O. Thompson, Cyclodextrins-enabling excipients: their present and future use in pharmaceuticals, Crit. Rev. Ther. Drug Carrier Syst. 14 (1997) 1-104.
39. A.M. Totterman, N.G. Schipper, D.O. Thompson, J.P. Mannermaa, Intestinal safety of water-soluble β-cycIodextrins in paediatric oral solutions of spironolactone: effects on human intestinal epithelial Caco-2 cells, J. Pharm. Pharmacol. 49 (1997) 43-48.
40. T. Jansen, B. Xhonneux, J. Mesens, M. Borgers, Beta-cyclodextrins as vehicles in eye-drop formulation: an evaluation of their effects on rabbit corneal epithelium, Lens Eye Toxicity Res. 7 (1990) 459-468.
41. J.C. Javitt, N.B. Javitt, P. McDonnell, Topical Compositions for the Eye Comprising a Beta-Cyclodextrin Derivative and a Carbonic Anhydrase Inhibitor, International Patent Application No. WO 94/15582, 1994.
42. H. Ohvo, J.P. Slotte, Cyclodextrin-inediated removal of sterols from monolayers: effects of sterol structure and phospholipids on desorption rate, Biochemistry 35 (1996) 8018-8024.
43. B. Siefert, S. Keipert, Influence of α-cyclodextrin and hydroxyalkylated β-cyclodextrin derivatives on the in vitro corneal uptake and permeation of aqueous pilocarpine-HCl solutions, J. Pharm. Sci. 86 (1997) 716-720.
44. E. Stefánsson, S. Thórisdóttir, Ó.G. Gudmundsson, T. Loftsson, H. Fridriksdóttir, J.K. Kristinsson, 2-hydroxypropyl-β-cyclodextrin in eye drops. Evaluation of artificial tear-drops in human patients, in: J. Szejtli, L. Szente L (Eds.), The Eighth International Symposium on Cyclodextrins, Kluwer Academic Publishing, Dordrecht, 1996, pp. 391-394.
45. T. Loftsson, E. Stefánsson, J.K. Kristinsson, H. Fridriksdóttir, T. Sverrisson, G. Gudmundsdóttir, S. Thórisdóttir, Topically effective acetazolamide eye-drop solution in man, Pharm. Sci. 6 (1996) 277-279.
46. T. Jarvinen, K. Jarvinen, A. Urtti, D. Thompson, V.J. Stella, Sulfobutyl ether β-cyclodextrin (SBE-β-CyD) in eye drops improves the tolerability of a topically applied pilocarpine prodrug in rabbits, J. Ocul. Pharmacol. Ther. 11 (1995) 95-106.
47. P. Jarho, K. Järvinen, A. Urtti, V.J. Stella, T. Jarvinen, Modified β-cyclodextrin (SBE7-β-CyD) with viscous vehicle improves the ocular delivery and tolerability of pilocarpine prodrug in rabbits, J. Pharm. Pharmacol. 48 (1996) 264-270.
48. A. Kanai, R.M. Alba, T. Takano, C. Kobayashi, A. Nakajima, K. Kurihara, T. Yokoyaina, M. Fukamni, The effect on the cornea of alpha cyclodextrin vehicle for cyclosporin eye drops, Transplant Proc. 21 (1989) 3150-3152.
49. P. Saarinen-Savolainen, T. Järvinen, K. Araki-Sasaki, H. Watanabe, A. Urtti, Evaluation of cytotoxicity of various ophthalmic drugs, eye drop excipients and Cyclodextrins in an immortalized human corneal epithelium cell line, Pharm. Res. 15 (1998) 1275-1280.
50. A. Urtti, Delivery of antiglaucoma drugs: ocular vs systemic absorption, J. Ocular Pharmacol. 10 (1994) 349-357.
51. C. LeBourlais, L. Acar, H. Zia, P.A. Sado, T. Needham, R. Leverge, Ophthalmic drug delivery systems-recent advances, Prog. Retinal Eye Res. 17 (1998) 33-58.
52. K.H. Frömming, J. Szejtli, Cyclodextrins in Pharmacy, Kluwer Academic Publishers, Dordrecht, 1994.
53. T. Loftsson, N. Bodor, The effect of cyclodextrins on percutaneous transport of drugs. In: E.W. Smith, H.I. Maibach (Eds.), Percutaneous Penetration Enhancers. CRC Press, Boca Raton, Florida, 1995, pp. 335-342.
54. J.C. Lang, M.M. Stiemke, Biological barriers to ocular delivery. In: I.K. Reddy (Ed.), Ocular Therapeutics and Drug Delivery. A Multi-disciplinary Approach. Technomic Publishing, Lancaster, Pennsylvania, 1996, pp. 51-132.
55. P. Jarho, K. Jarvinen, A. Urtti, V.J. Stella, T. Jarvinen, The effect of SBE7-β-cyclodextrin with viscous vehicle on ocular delivery of pilocarpine prodrug in rabbits, in: J. Szejtli, L. Szente, (Eds.), The Eigth International Symposium on Cyclodextrins, Kluwer Academic Publishers, Dordrecht, 1997, pp. 299-402.
56. P. Jarho, A. Urtti, D.W. Pate, P. Suhonen, T. Järvinen, Increase in aqueous solubility, stability and in vitro corneal permeability of anandamide by hydroxypropyl-β-cyclodextrin, Int. J. Pharm. 137 (1996) 209-217.
57. A.M. Sigurdardottir, T. Loftsson, The effect of polyvinylpyrrolidone on cyclodextrin complexation of hydrocortisone and its diffusion through hairless mouse skin, Int. J. Pharm. 126 (1995) 73-78.
58. H. Kublik, T.K. Bock, H. Schreier, B.W. Müller, Nasal absorption of 17β-estradiol from different cyclodextrin inclusion formulations in sheep, Eur. J. Pharm. Biopharm. 42 (1996) 320-324.
59. D. Duchêne, D. Wouessidjewe, Pharmaceutical and medical applications of cyclodextrins, in: S. Dumitriu (Ed.), Polysaccharides In Medical Applications, Marcel Dekker, New York, 1996, pp. 575-602.
60. M. Másson, T. Loftsson, E. Stefánsson, How do cyclodextrins enhance drug permeability through biological membranes? in: J.J. Torres-Labandeira. (Ed.), Ninth International Symposium on Cyclodextrins, Santiago de Compostela, Kluwer Academic Publishers, Dordrecht, 1998 in print.
61. T. Higuchi, Physical chemical analysis of percutaneous absorption process from creams and ointments, J. Soc. Cosmetic Chemists 11 (1960) 85-97.
62. F.J. Otero Espinar, S. Anguiano, M.J. Blanco, J.J.L. Vila, Reduction in the ulcerogenicity of naproxen by complexation with β-cyclodextrin, Int. J. Pharm. 70 (1991) 35-41.
63. S.-L. Lin, D. Wouessidjewe, M.-C. Poelman, D. Duchêne, In vivo evaluation of indomnethacin/cyclodextrin complexes gastrointestinal tolerance and dermal anti-inflammatory activity, Int. J. Pharm. 106 (1994) 63-67.
64. L. Patoia, G. Clausi, F. Farroni, P. Alberti, P. Fugiani, L. Bufalino, Comparison of faecal blood loss, upper gastrointestinal mucosal integrity and symptoms after piroxicam beta-cyclodextrin, pyroxicam and placebo administration, Eur. J. Clin. Pharmacol. 36 (1989) 599-604.
65. G. Puglisi, N.A. Santagati, C.A. Ventura, R. Pignatello, A. Panico, Enhancement of 4-biphenylacetic acid bioavailability in rats by its β-cyclodextrin complex after oral administration, J. Pharm. Pharmacol. 43 (1991) 430-432.
66. A. Yoshida, M. Yamamoto, T. Itoh, T. Irie, F. Hirayama, K. Uekama, Utility of 2-hydroxypropyl-β-cyclodextrin in an intramuscular injectable preparation of nimodipine, Chem. Pharm. Bull. 38 (1990) 176-179.
67. V.J. Stella, H.K. Lee, D.O. Thompson, The effect of SBE4-β-CD on i.m. prednisolone pharmacokinetics and tissue damage in rabbits: comparison to a co-solvent solution and a water-soluble prodrug, Int. J. Pharm. 120 (1995) 197-204.
68. T. Järvinen, P. Suhonen, A. Urtti, P. Peura, O,O′-(1,4-xylylene)bispilocarpic acid esters as new potential double prodrugs of pilocarpine for improvement of ocular delivery. II. Physochemical properties, stability, solubility and enzymatic hydrolysis, Int. J. Pharm. 75 (1991) 259-269.
69. P. Suhonen, T. Järvinen, K. Lehmussaari, T. Reunamäki, A. Urtti, Rate control of ocular pilocarpine delivery with bispilocarpic acid diester, Int. J. Pharm. 127 (1996) 85-94.
70. P. Suhonen, T. Järvinen, K. Lehmussaari, T. Reunamäki, A. Urtti, Ocular absorption and irritation of pilocarpine prodrug is modified with buffer, polymer, and cyclodextrin in the eyedrop, Pharm. Res. 12 (1995) 529-533.
71. K. Nakanishi, M. Masada, T. Nadai, K. Miyajima, Effect of the interaction of drug-β-cyclodextrin complex with bile salts on the drug absorption from rat small intestinal lumen, Chem. Pharm. Bull. 37 (1989) 211-214.
72. H.W. Frijlink, A.C. Eissens, A.J.M. Schoonen, C.F. Lerk, The effect of cyclodextrins on drug absorption. II. In vivo observation, Int. J. Pharm. 64 (1990) 195-205.
73. Y. Ikejiri, F. Tokomochi, S. Sameshima, M. Kimura, Antiallergic Composition for Ophthalmic or Nasal Use, Eur. Pat. Appl. 1 605 203 A3, 1994.
74. K. Ushio, Y. Ikejiri Y, Composition for Eyedrops. Eur. Pat. Appl. No. 0472 327 A1, 1992.
75. T. Loftsson, Effects of cyclodextrins on the chemical stability of drugs in aqueous solutions, Drug Stability 1 (1995) 22-33.
76. T. Loftsson, M.E. Brewster, Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization, J. Pharm. Sci. 85 (1996) 1017-1025.
77. E. Albers, B.W. Müller, Cyclodextrin derivatives in pharmaceutics, Crit. Rev. Ther. Drug Carrier Syst. 12 (1995) 311-337.
78. D. Teshimna, K. Otsubo, S. Higuchi, F. Hirayamna, K. Uckama, T. Aoyama, Effects of cyclodextrins on degredations of emetine and cephaeline in aqueous solution, Chem. Pharm. Bull. 37 (1989) 1591-1594.
79. J. Mielcarek, Photochemical stability of the inclusion complexes of nicardipine with α-, γ-cyclodextrin, methyl-β-cyclodextrin and hydroxypropyl-β-cyclodextrin in solid state and in solution, Pharmazie 51 (1996) 477-479.
80. Y. Aso, S. Yoshioka, Y. Takeda, Epimerization and racemization of some chiral drugs in the presence of cyclodextrin and lipopsomes, Chem. Pharm. Bull. 37 (1989) 2786-2789.
81. T. Loftsson, B.J. Ólafsdóttir, Cyclodextrin-accelerated degradation of β-lactam antibiotics in aqueous solutions, Int. J. Pharm. 67 (1991) R5-R7.
82. T. Backensfeld, B. Müller, K. Kolter, Interaction of NSA with Cyclodextrins and hydroxypropyl cyclodextrin derivatives, Int. J. Pharm. 74 (1991) 85-93.
83. S. Choundry, A.K. Mitra, Kinetics of aspirin hydrolysis and stabilization in presence of 2-hydroxypropyl-β-cyclodextrin, Pharm. Res. 10 (1993) 156-159.
84. F. Liu, D.O. Kildsig, A.K. Mitra, cyclodextrin/weak-electrolyte complexation: interpretation and estimation of association constants from phase solubility diagrams, Pharm. Res. 9 (1992) 1671-1672.
85. M.T. Esclusa-Diaz, M. Guimaraens-Mendez, M.B. Perez-Marcos, Characterization and in vitro dissolution behaviour of ketakonazole/β- and 2-hydroxypropyl-β-cyclodextrin inclusion compounds, Int. J. Pharm. 143 (1996) 203-210.
86. K. Okimoto, R.A. Rajewski, K. Uekama, J.A. Jona, V.J. Stella, The interaction of charged and uncharged drugs with neutral (HP-β-CD) and anionically charged (SBE7-β-CD) β-cyclodextrins, Pharm. Res. 13 (1996) 256-264.
87. A. Hussain, J.E. Truelove, Prodrug approaches to enhancement of physicochemical properties of drugs. IV: novel epinephrine prodrug, J. Pharm. Sci. 72 (1976) 1510-1512.
88. A.I. Mandell, F. Stentz, Dipivalyl epinephrine: a new prodrug in the treatment of glaucoma, Ophthalmol. 85 (1978) 268-275.
89. A.N. Kohn, A.P. Moss, N.A. Hargett, R. Ritch, H. Smith, S.M. Podos, Clinical comparison of dipivalyl epinephrine and epinephrine in the treatment of glaucoma. Am. J. Ophthalmol. (1979) 87.
90. USP DI, Drug Information for the Health Care Professional, 10th ed. United States Pharmacopeial Convention, 1990.
91. P. Jarho, K. Järvinen, A. Urtti, V.J. Stella, T. Järvinen, The use of Cyclodextrins in ophthalmic formulations of dipivefrin, Int. J. Pharm. 153 (1997) 225-233.
92. K. Järvinen, T. Järvinen, D.O. Thompson, V. Stella, The effect of modified β-cyclodextrin, SBE4-β-CD, on the aqueous solubility and ocular absorption of pilocarpine, Curr. Eye Res. 13 (1994) 891-905.
93. N.M. Davies, G. Wang, I.G. Tucker, Evaluation of a hydrocortisone/hydroxypropyl-β-cyclodextrin solution for ocular drug delivery, Int. J. Pharm. 156 (1997) 201-209.
94. A. Usayapant, A.H. Karara, M.M. Narurkar, Effect of 2-hydroxypropyl-β-cyclodextrin on the ocular absorbtion of dexamethazone and dexamethazoneacetat, Pharm. Res. 12 (1991) 1495-1499.
95. D.W. Pate, K. Järvinen, A. Urtti, P. Jarho, T. Järvinen, Ophthalmic arachidonylethanolamide decreases intraocular pressure in normotensive rabbits, Curr. Eye Res. 14 (1995) 791-797.
96. D.W. Pate, K. Järvinen, A. Urtti, P. Jarho, F. Mette, V. Mahadevan, T. Järvinen, Effects of topical anandamides on intraocular pressure in normotensive rabbits, Life Sci. 58 (1996) 1849-1860.
97. D.W. Pate, K. Jarvinen, A. Urtti, P. Jarho, F. Mette, V. Mahadevan, T. Järvinen, Effects of topical alpha-substituted anandamide on intraocular pressure in normotensive rabbits, Pharm. Res. 14 (1996) 1738-1743.
98. T. Loftsson, H. Fridriksdottir, A.M. Sigurdardottir, H. Ueda, The effect of water-soluble polymers on drug-cyclodextrin complexation, Int. J. Pharm. 110 (1994) 169-177.
99. T. Loftsson, H. Fridriksdóttir, The effect of water-soluble polymers on the aqueous solubility and complexing abilities of β-cyclodextrin, Int. J. Pharm. 163 (1998) 115-121.
100. J.K. Kristinsson, H. Fridriksdóttir, S. Thórisdóttir, A.M. Sigurdardóttir, E. Stefánsson, T. Loftsson, Dexamethasone-cyclodextrin-polymer cocomplexes in aqueous eye drops, Inv. Ophthalmol. Vis. Sci. 37 (1996) 1199-1203.
101. D. Attwood, A.T. Florence, Surfactant Systems, Their Chemistry, Pharmacy and Biology, Chapmann and Hall, London, 1983.
102. D. Myers, Surfactant Science and Technology, VCH Publishers, New York, 1998.
103. J.C. Brackman, J.B.F.N. Engberts, Polymer-micelle interactions: physical organic aspects. Chem. Soc. Rev. (1993) 85-92.
104. T. Loftsson, H. Fridriksdóttir, E. Stefánsson, S. Thórisdóttir, Ö. Gudmundsson, T. Sigthórsson, Topically effective ocular hypertensive acetazolamide and ethoxyzolamide formulations in rabbits, J. Pharm. Pharmacol. 46 (1994) 503-504.
105. L. Cheeks, R.L. Kaswan, K. Green, Influence of vehicle and anterior chamber protein concentration on cyclosporin penetration through the isolated rabbit cornea, Curr. Eye Res. 11 (1992) 641-649.
106. T. Loftsson, H. Fridriksdottir, S. Thorisdottir, E. Stefansson, The effect of hydroxypropyl methylcellulose on release of dexamethazone from aqueous 2-hydroxypropyl-β-cyclodextrin formulations, Int. J. Pharm. 104 (1994) 181-184.
107. O. Reer, T.K. Bock, B.W. Müller, In vitro corneal permeability of diclofenac sodium in formulations containing cyclodextrins compared to commercial product voltaren ophtha, J. Pharm. Sci. 83 (1994) 1345-1349.
108. K.A. Freedman, J.W. Klein, C.E. Crosson, Beta-cyclodextrins enhance biovailability of pilocarpine, Curr. Eye Res. 12 (1993) 641.
109. S. Keipert, J. Fedder, A. Bohm, B. Hanke, Interactions between Cyclodextrins and pilocarpine-as an example of a hydrophilic drug, Int. J. Pharm. 142 (1996) 153-162.
110. L.A. Wheeler, The use of inclusion complexes of prostaglandins with Cyclodextrins in the treatment of ocular hypertension, Eur. Pat. No. 0435 682 A3, 1991.
111. R. Lazare, M. Horlington, Pilocarpine levels in the eyes of rabbits following topical application, Exp. Eye Res. 21 (1975) 281-287.
112. N. Unlü, M. Sumnu, A.A. Hincal, Formulation studies on pilocarpine nitrate ophthalmic solutions, Acta Pharm. Technol. 35 (1989) 38-43.
113. T. Loftsson, H. Fridriksdóttir, S. Thórisdóttir, E. Stefánsson, A.M. Sigurdardóttir, Ö. Gudmundsson, T. Sigthórsson, 2-Hydroxypropyl-β-cyclodextrinin topical carbonic anhydrase inhibitor formations, Eur. J. Pharm. Sci. 1 (1994) 175-180.
114. S.J. Lehner, B.W. Müller, J.K. Seydel, Effect of hydroxypropyl-β-cyclodextrin on the antimicrobial action of preservatives, J. Pharm. Pharmacol. 46 (1994) 186-191.
115. T. Loftsson, Ó. Stefansdottir, H. Fridriksdottir, Ö. Gudmundsson, Interaction between preservatives and 2-hydroxypropyl-β-cyclodextrin, Drug Devel. Ind. Pharm. 18(13) (1992) 1477-1484.
116. S.J. Lehner, B.W. Müller, J.K. Seydel, Interactions between p-hydroxybenzoic acid esters and hydroxypropyl-β-Cyclodextrins and their antimicrobial effect against Candida albicans, Int. J. Pharm. 93 (1993) 201-208.
117. G.L. Kis, A. Fetz, C. Schoch, Ophthalmic compositions containing Cyclodextrins and quaternary ammonium compounds, Int. Pat. Appl. No. WO 97/10805, 1997.
118. H. Matsuda, K. Ito, Y. Sato, D. Yoshizava, M. Tanaka, A. Taki, H. Suiniyoshi, T. Utsuki, F. Hirayama, K. Uekama, Inclusion complexation of p-hydroxybenzoic acid esters with 2-hydroxypropyl-β-cyclodextrin. On changes in solubility and antimicrobial activity, Chem. Pharm. Bull. 41 (1993) 1448-1452.
119. T.H. Maren, Process for reducing intraocular pressure, United States Patent No. 4,619,939, 1986, p. 6.
120. F. Fridriksdóttir, Polymer Enhancement of Cyclodextrin Complexation, Department of Pharmacy. University of Iceland, Reykjavik, 1997, pp. 113.
121. M. Wilkerson, M. Cyrlin, E. Lippa, Four-week safety and efficacy study of Dorzolamide, a novel, active topical carbonic anhydrase inhibitor, Arch. Ophtalmol. 111 (1993) 1343-1350.
122. K.M. Saari, H. Jyrkkiö, H. Seppa, T. Loftsson, E. Stefansson, Acute and Chronic Postoperative Inflammatory Reactions after Cateract Extraction and Intraocular Lens Implantation, Excerta Medica International Congress, 1998, p. 1158.